Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2016, Article ID 9498013, 11 pages
http://dx.doi.org/10.1155/2016/9498013
Review Article

Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A Systematic Review

1Department of Nephrology, Nicosia General Hospital, 2230 Nicosia, Cyprus
2Cyprus International Institute for Environmental & Public Health in Association with Harvard T. H. Chan School of Public Health, Cyprus University of Technology, 3041 Limassol, Cyprus

Received 24 November 2015; Revised 22 January 2016; Accepted 8 February 2016

Academic Editor: Hermann Haller

Copyright © 2016 Andreas Kousios et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Foley, A. M. Murray, S. Li et al., “Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999,” Journal of the American Society of Nephrology, vol. 16, no. 2, pp. 489–495, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Saran, Y. Li, B. Robinson et al., “US renal data system 2014 annual data report: epidemiology of kidney disease in the United States,” American Journal of Kidney Diseases, vol. 66, supplement 1, article A7, no. 1, 2015. View at Publisher · View at Google Scholar
  3. C. Daly, “Is early chronic kidney disease an important risk factor for cardiovascular disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 22, supplement 9, pp. ix19–ix25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. C. Gerstein, J. F. E. Mann, Q. Yi et al., “Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals,” The Journal of the American Medical Association, vol. 286, no. 4, pp. 421–426, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., “Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention,” Circulation, vol. 108, no. 17, pp. 2154–2169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Schwarz, M. Buzello, E. Ritz et al., “Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure,” Nephrology Dialysis Transplantation, vol. 15, no. 2, pp. 218–223, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimbürger, and Z. Massy, “Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?” Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 505–521, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. W. Lorenz, H. S. Markus, M. L. Bots, M. Rosvall, and M. Sitzer, “Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis,” Circulation, vol. 115, no. 4, pp. 459–467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Coll, Á. Betriu, M. Martínez-Alonso et al., “Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment,” Nephrology Dialysis Transplantation, vol. 25, no. 9, pp. 3017–3025, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Matsushita, Y. Sang, S. H. Ballew et al., “Subclinical atherosclerosis measures for cardiovascular prediction in CKD,” Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 439–447, 2015. View at Publisher · View at Google Scholar
  11. R. Visse and H. Nagase, “Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry,” Circulation Research, vol. 92, no. 8, pp. 827–839, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Tan and Y. Liu, “Matrix metalloproteinases in kidney homeostasis and diseases,” The American Journal of Physiology—Renal Physiology, vol. 302, no. 11, pp. F1351–F1361, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. T. H. Vu and Z. Werb, “Matrix metalloproteinases: effectors of development and normal physiology,” Genes and Development, vol. 14, no. 17, pp. 2123–2133, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Rodríguez, C. J. Morrison, and C. M. Overall, “Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1803, no. 1, pp. 39–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. S. Galis and J. J. Khatri, “Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly,” Circulation Research, vol. 90, no. 3, pp. 251–262, 2002. View at Google Scholar · View at Scopus
  16. D. Fukuda, K. Shimada, A. Tanaka et al., “Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris,” American Journal of Cardiology, vol. 97, no. 2, pp. 175–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Alvarez, C. Ruiz, P. Chacón, J. Alvarez-Sabin, and M. Matas, “Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis,” Journal of Vascular Surgery, vol. 40, no. 3, pp. 469–475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Orbe, I. Montero, J. A. Rodríguez, O. Beloqui, C. Roncal, and J. A. Páramo, “Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis,” Journal of Thrombosis and Haemostasis, vol. 5, no. 1, pp. 91–97, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Tan, Y. Liu, W. Li et al., “Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness,” Atherosclerosis, vol. 232, no. 1, pp. 199–203, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Goncalves, E. Bengtsson, H. M. Colhoun et al., “Elevated plasma levels of MMP-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 7, pp. 1723–1731, 2015. View at Publisher · View at Google Scholar
  21. P. Sapienza, V. Borrelli, L. di Marzo, and A. Cavallaro, “MMP and TIMP alterations in asymptomatic and symptomatic severe recurrent carotid artery stenosis,” European Journal of Vascular and Endovascular Surgery, vol. 37, no. 5, pp. 525–530, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. K.-F. Wang, P.-H. Huang, C.-H. Chiang et al., “Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction,” Coronary Artery Disease, vol. 24, no. 1, pp. 23–28, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. K. J. Molloy, M. M. Thompson, J. L. Jones et al., “Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity,” Circulation, vol. 110, no. 3, pp. 337–343, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Fiotti, N. Altamura, C. Orlando et al., “Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI,” International Journal of Cardiology, vol. 127, no. 3, pp. 350–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Li, L. Li, H. R. Zielke et al., “Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions,” The American Journal of Pathology, vol. 148, no. 1, pp. 121–128, 1996. View at Google Scholar · View at Scopus
  26. M. Wang, S. H. Kim, R. E. Monticone, and E. G. Lakatta, “Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis,” Hypertension, vol. 65, no. 4, pp. 698–703, 2015. View at Publisher · View at Google Scholar
  27. S. Lenglet, A. Thomas, P. Chaurand, K. Galan, F. Mach, and F. Montecucco, “Molecular imaging of matrix metalloproteinases in atherosclerotic plaques,” Thrombosis and Haemostasis, vol. 107, no. 3, pp. 409–416, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. R. E. Vandenbroucke and C. Libert, “Is there new hope for therapeutic matrix metalloproteinase inhibition?” Nature Reviews Drug Discovery, vol. 13, pp. 904–927, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. A. C. Newby, “Metalloproteinases promote plaque rupture and myocardial infarction: a persuasive concept waiting for clinical translation,” Matrix Biology, vol. 44–46, pp. 157–166, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. G. Cerisano, P. Buonamici, A. M. Gori et al., “Matrix metalloproteinases and their tissue inhibitor after reperfused ST-elevation myocardial infarction treated with doxycycline. Insights from the TIPTOP trial,” International Journal of Cardiology, vol. 197, pp. 147–153, 2015. View at Publisher · View at Google Scholar
  31. J. J. Carrero and P. Stenvinkel, “Inflammation in end-stage renal disease-what have we learned in 10 years?” Seminars in Dialysis, vol. 23, no. 5, pp. 498–509, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. O. M. Akchurin and F. Kaskel, “Update on inflammation in chronic kidney disease,” Blood Purification, vol. 39, no. 1–3, pp. 84–92, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Wells, B. Shea, D. O'connell et al., The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses, Ottawa Hospital Research Institute, Ottawa, Canada, 2000, http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm.
  34. P.-J. Touboul, M. G. Hennerici, S. Meairs et al., “Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011,” Cerebrovascular Diseases, vol. 34, no. 4, pp. 290–296, 2012. View at Publisher · View at Google Scholar
  35. C. I. K. Weber, G. Duchateau-Nguyen, C. Solier et al., “Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4,” Clinical Kidney Journal, vol. 7, no. 2, pp. 167–173, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Sánchez-Escuredo, M. C. Pastor, B. Bayés et al., “Inflammation, metalloproteinases, and growth factors in the development of carotid atherosclerosis in renal transplant patients,” Transplantation Proceedings, vol. 42, no. 8, pp. 2905–2907, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Addabbo, F. Mallamaci, D. Leonardis et al., “Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function,” Nephrology Dialysis Transplantation, vol. 22, no. 12, pp. 3521–3526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Coll, J. A. Rodríguez, L. Craver et al., “Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease,” Kidney International, vol. 78, no. 12, pp. 1275–1280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Pawlak, D. Pawlak, and M. Mysliwiec, “Extrinsic coagulation pathway activation and metalloproteinase-2/TIMPs system are related to oxidative stress and atherosclerosis in hemodialysis patients,” Thrombosis and Haemostasis, vol. 92, no. 3, pp. 646–653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Pawlak, D. Pawlak, and M. Myśliwiec, “Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients,” Thrombosis Research, vol. 121, no. 4, pp. 543–548, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Nagano, K. Fukami, S.-I. Yamagishi et al., “Circulating matrix metalloproteinase-2 is an independent correlate of proteinuria in patients with chronic kidney disease,” American Journal of Nephrology, vol. 29, no. 2, pp. 109–115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Belal, M. El Deeb, N. Adly, M. Mostafa, K. Kaffas, and N. Mohammed, “The relationship between Matrix Metalloproteinase-10 (MMP-10) and atherosclerosis in patients with chronic kidney disease,” International Journal of Advanced Research, vol. 2, no. 10, pp. 409–430, 2014. View at Google Scholar
  43. M. S. M. Issac, A. Afif, N. A. Gohar et al., “Association of E-selectin gene polymorphism and serum PAPP-A with carotid atherosclerosis in end-stage renal disease,” Molecular Diagnosis & Therapy, vol. 18, no. 2, pp. 243–252, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Peiskerová, M. Kalousová, M. Kratochvílová et al., “Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?” Kidney and Blood Pressure Research, vol. 32, no. 4, pp. 276–283, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Pawlak, J. Tankiewicz, M. Mysliwiec, and D. Pawlak, “Systemic levels of MMP2/TIMP2 and cardiovascular risk in CAPD patients,” Nephron Clinical Practice, vol. 115, no. 4, pp. c251–c258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Musiał and D. Zwolińska, “Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment,” Cell Stress and Chaperones, vol. 16, no. 1, pp. 97–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Siasos, D. Tousoulis, S. Kioufis et al., “Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases,” Current Topics in Medicinal Chemistry, vol. 12, no. 10, pp. 1132–1148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Amin, S. Pushpakumar, N. Muradashvili, S. Kundu, S. C. Tyagi, and U. Sen, “Regulation and involvement of matrix metalloproteinases in vascular diseases,” Frontiers in Bioscience, vol. 21, pp. 89–118, 2016. View at Google Scholar
  49. P. Brunet, B. Gondouin, A. Duval-Sabatier et al., “Does uremia cause vascular dysfunction?” Kidney and Blood Pressure Research, vol. 34, no. 4, pp. 284–290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Pelisek, I. N. Hahntow, H.-H. Eckstein et al., “Impact of chronic kidney disease on carotid plaque vulnerability,” Journal of Vascular Surgery, vol. 54, no. 6, pp. 1643–1649, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. U. Baber, G. W. Stone, G. Weisz et al., “Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes,” JACC: Cardiovascular Imaging, vol. 5, no. 3, pp. S53–S61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Kono, H. Fujii, K. Nakai et al., “Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease,” Kidney International, vol. 82, no. 3, pp. 344–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Lim and S. Park, “Role of vascular smooth muscle cell in the inflammation of atherosclerosis,” BMB Reports, vol. 47, no. 1, pp. 1–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. A. C. Newby, “Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates,” Cardiovascular Research, vol. 69, no. 3, pp. 614–624, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. A. C. Newby, “Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture,” Physiological Reviews, vol. 85, no. 1, pp. 1–31, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. P. Libby, “Collagenases and cracks in the plaque,” Journal of Clinical Investigation, vol. 123, no. 8, pp. 3201–3203, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Pawlak, M. Mysliwiec, and D. Pawlak, “Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis,” Clinical Biochemistry, vol. 44, no. 10-11, pp. 838–843, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. R. S. Friese, F. Rao, S. Khandrika et al., “Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease,” Clinical and Experimental Hypertension, vol. 31, no. 7, pp. 521–533, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. A. W. Y. Chung, H. H. Clarice Yang, J. M. Kim et al., “Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease,” Circulation, vol. 120, no. 9, pp. 792–801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. A. W. Y. Chung, H. H. C. Yang, M. K. Sigrist et al., “Matrix metalloproteinase-2 and-9 exacerbate arterial stiffening and angiogenesis in diabetes and chronic kidney disease,” Cardiovascular Research, vol. 84, no. 3, pp. 494–504, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Drucker and K. Krapfenbauer, “Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine,” EPMA Journal, vol. 4, no. 1, p. 7, 2013. View at Publisher · View at Google Scholar
  62. G. B. Fields, “New strategies for targeting matrix metalloproteinases,” Matrix Biology, vol. 44–46, pp. 239–246, 2015. View at Publisher · View at Google Scholar
  63. A. Papazafiropoulou and N. Tentolouris, “Matrix metalloproteinases and cardiovascular diseases,” Hippokratia, vol. 13, no. 2, pp. 76–82, 2009. View at Google Scholar · View at Scopus
  64. K. Jung, C. Laube, M. Lein et al., “Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood,” Clinical Chemistry, vol. 44, no. 5, pp. 1060–1062, 1998. View at Google Scholar · View at Scopus
  65. K. Jung, S. Klotzek, C. Stephan, F. Mannello, and M. Lein, “Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9,” Clinical Chemistry, vol. 54, no. 4, pp. 772–773, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Rysz, M. Banach, R. A. Stolarek et al., “Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis,” International Urology and Nephrology, vol. 43, no. 2, pp. 491–498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. F.-P. Chou, S.-C. Chu, M.-C. Cheng et al., “Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors,” Clinical Biochemistry, vol. 35, no. 5, pp. 383–388, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Janssens and H. R. Lijnen, “What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?” Cardiovascular Research, vol. 69, no. 3, pp. 585–594, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. I. Konstantinidis, G. N. Nadkarni, R. Yacoub et al., “Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review,” JAMA Internal Medicine, vol. 176, no. 1, pp. 121–124, 2016. View at Publisher · View at Google Scholar
  70. V. Jha, G. Garcia-Garcia, K. Iseki et al., “Chronic kidney disease: global dimension and perspectives,” The Lancet, vol. 382, no. 9888, pp. 260–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. C. S. Fox, P. Muntner, A. Y. Chen et al., “Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the national cardiovascular data acute coronary treatment and intervention outcomes network registry,” Circulation, vol. 121, no. 3, pp. 357–365, 2010. View at Publisher · View at Google Scholar · View at Scopus